{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T06:28:04Z","timestamp":1782368884144,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["U01 CE00278"],"award-info":[{"award-number":["U01 CE00278"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s11606-020-06192-4","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T18:15:30Z","timestamp":1600193730000},"page":"3188-3196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Prescription Opioid Dispensing Patterns Prior to Heroin Overdose in a State Medicaid Program: a Case-Control Study"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0685-773X","authenticated-orcid":false,"given":"Daniel M.","family":"Hartung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirbee A.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hallvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Leichtling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonah","family":"Geddes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christi","family":"Hildebran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shellie","family":"Keast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Todd","family":"Korthuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,15]]},"reference":[{"key":"6192_CR1","doi-asserted-by":"crossref","unstructured":"Jalal H, Buchanich JM, Roberts MS, Balmert LC, Zhang K, Burke DS. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science. 2018:21:361(6408).","DOI":"10.1126\/science.aau1184"},{"key":"6192_CR2","unstructured":"Hedegaard H, Minino AM, Warner M. Drug Overdose Deaths in the United States, 1999-2017. NCHS data brief 2018:1\u20138."},{"key":"6192_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMra1508490","volume":"374","author":"WM Compton","year":"2016","unstructured":"Compton WM, Jones CM, Baldwin GT. Relationship between Nonmedical Prescription-Opioid Use and Heroin Use. N Engl J Med 2016;374:154\u2013163.","journal-title":"N Engl J Med"},{"key":"6192_CR4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1001\/jamapsychiatry.2014.366","volume":"71","author":"TJ Cicero","year":"2014","unstructured":"Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA psychiatry 2014;71:821\u2013826.","journal-title":"JAMA psychiatry"},{"key":"6192_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.drugalcdep.2013.01.007","volume":"132","author":"CM Jones","year":"2013","unstructured":"Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010. Drug Alcohol Depend 2013;132:95\u2013100.","journal-title":"Drug Alcohol Depend"},{"key":"6192_CR6","doi-asserted-by":"crossref","unstructured":"Ciccarone D. The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019;71:183\u2013188.","DOI":"10.1016\/j.drugpo.2019.01.010"},{"key":"6192_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.addbeh.2018.05.030","volume":"87","author":"TJ Cicero","year":"2018","unstructured":"Cicero TJ, Kasper ZA, Ellis MS. Increased use of heroin as an initiating opioid of abuse: Further considerations and policy implications. Addict Behav 2018;87:267\u201371.","journal-title":"Addict Behav"},{"key":"6192_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1377\/hlthaff.2018.05232","volume":"38","author":"D Powell","year":"2019","unstructured":"Powell D, Alpert A, Pacula RL. A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C. Health affairs (Project Hope) 2019;38:287\u2013294.","journal-title":"Health affairs (Project Hope)"},{"key":"6192_CR9","doi-asserted-by":"crossref","unstructured":"Cicero TJ, Ellis MS. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin. JAMA Psychiatry 2015;72:424\u2013430.","DOI":"10.1001\/jamapsychiatry.2014.3043"},{"key":"6192_CR10","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMc1505541","volume":"373","author":"TJ Cicero","year":"2015","unstructured":"Cicero TJ, Ellis MS, Harney J. Shifting Patterns of Prescription Opioid and Heroin Abuse in the United States. N Engl J Med 2015;373:1789\u20131790.","journal-title":"N Engl J Med"},{"key":"6192_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1056\/NEJMc1204141","volume":"367","author":"TJ Cicero","year":"2012","unstructured":"Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 2012;367:187\u2013189.","journal-title":"N Engl J Med"},{"key":"6192_CR12","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.2016.1464","volume":"315","author":"D Dowell","year":"2016","unstructured":"Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. Jama 2016;315:1624-1645.","journal-title":"Jama"},{"key":"6192_CR13","doi-asserted-by":"crossref","unstructured":"Deyo RA, Hallvik SE, Hildebran C, et al. Association of Prescription Drug Monitoring Program Use With Opioid Prescribing and Health Outcomes: A Comparison of Program Users and Nonusers. J Pain. 2018.19:166\u2013177.","DOI":"10.1016\/j.jpain.2017.10.001"},{"key":"6192_CR14","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/pds.4254","volume":"26","author":"DM Hartung","year":"2017","unstructured":"Hartung DM, Ahmed SM, Middleton L, et al. Using prescription monitoring program data to characterize out-of-pocket payments for opioid prescriptions in a state Medicaid program. Pharmacoepidemiol Drug Saf 2017;26:1053\u20131060.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6192_CR15","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.15585\/mmwr.mm675152e1","volume":"67","author":"L Scholl","year":"2018","unstructured":"Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and Opioid-Involved Overdose Deaths - United States, 2013-2017. MMWR Morb Mortal Wkly Rep 2018;67:1419\u20131427.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"6192_CR16","unstructured":"National Center for Injury Prevention and Control. CDC compilation of benzodiazepines, muscle relaxants, stimulants, zolpidem, and opioid analgesics with oral morphine milligram equivalent conversion factors, 2018 version. Atlanta, GA: Centers for Disease Control and Prevention; 2018. Available at https:\/\/www.cdc.gov\/drugoverdose\/resources\/data.html. Accessed 9\/10\/2020"},{"key":"6192_CR17","unstructured":"Pharmacy Quality Alliance: Opioid Core Measurement Set [online]. Available at: https:\/\/www.pqaalliance.org\/assets\/Measures\/PQA_Opioid_Core_Measure_Set_Description.pdf. Accessed Jun 16, 2019."},{"key":"6192_CR18","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/MLR.0000000000000735","volume":"55","author":"BJ Moore","year":"2017","unstructured":"Moore BJ, White S, Washington R, Coenen N, Elixhauser A. Identifying Increased Risk of Readmission and In-hospital Mortality Using Hospital Administrative Data: The AHRQ Elixhauser Comorbidity Index. Med Care 2017;55:698\u2013705.","journal-title":"Med Care"},{"key":"6192_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2147\/SAR.S24800","volume":"2","author":"RA Pollini","year":"2011","unstructured":"Pollini RA, Banta-Green CJ, Cuevas-Mota J, Metzner M, Teshale E, Garfein RS. Problematic use of prescription-type opioids prior to heroin use among young heroin injectors. Subst Abus Rehabil 2011;2:173\u2013180.","journal-title":"Subst Abus Rehabil"},{"key":"6192_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.7326\/M17-0865","volume":"167","author":"B Han","year":"2017","unstructured":"Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health. Ann Intern Med 2017;167:293\u2013301.","journal-title":"Ann Intern Med"},{"key":"6192_CR21","doi-asserted-by":"crossref","unstructured":"Kroenke K, Alford DP, Argoff C, Canlas B, Covington E, Frank JW\u00a0et al. Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report. Pain Medicine. 2019. Pain Med. 2019;20:724-735.","DOI":"10.1093\/pm\/pny307"},{"key":"6192_CR22","doi-asserted-by":"crossref","unstructured":"Dowell D, Haegerich T, Chou R. No Shortcuts to Safer Opioid Prescribing. N Engl J Med 2019.","DOI":"10.1056\/NEJMp1904190"},{"key":"6192_CR23","doi-asserted-by":"crossref","unstructured":"Fenton JJ, Agnoli AL, Xing G, Hang L, Altan AE, Tancredi DJ, et al.\u00a0Trends and Rapidity of Dose Tapering Among Patients Prescribed Long-term Opioid Therapy, 2008-2017. JAMA Netw Open. 2019;2:e1916271.","DOI":"10.1001\/jamanetworkopen.2019.16271"},{"key":"6192_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jsat.2019.05.001","volume":"103","author":"TL Mark","year":"2019","unstructured":"Mark TL, Parish W. Opioid medication discontinuation and risk of adverse opioid-related health care events. J Subst Abus Treat 2019;103:58-63.","journal-title":"J Subst Abus Treat"},{"key":"6192_CR25","doi-asserted-by":"publisher","first-page":"e192613","DOI":"10.1001\/jamanetworkopen.2019.2613","volume":"2","author":"JM Glanz","year":"2019","unstructured":"Glanz JM, Binswanger IA, Shetterly SM, Narwaney KJ, Xu S. Association Between Opioid Dose Variability and Opioid Overdose Among Adults Prescribed Long-term Opioid. JAMA Netw Open 2019;2:e192613-e192613.","journal-title":"JAMA Netw Open"},{"key":"6192_CR26","doi-asserted-by":"publisher","first-page":"m283","DOI":"10.1136\/bmj.m283","volume":"368","author":"EM Oliva","year":"2020","unstructured":"Oliva EM, Bowe T, Manhapra A, Kertesz S, Hah JM, Henderson P, et al. Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. BMJ. 2020;368:m283.","journal-title":"BMJ."},{"key":"6192_CR27","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s11606-019-05301-2","volume":"34","author":"JR James","year":"2019","unstructured":"James JR, Scott JM, Klein JW, Jackson S, McKinney C, Novack M, et al. Mortality After Discontinuation of Primary Care-Based Chronic Opioid Therapy for Pain: a Retrospective Cohort Study. J Gen Intern Med 2019;34:2749\u201355.","journal-title":"J Gen Intern Med"},{"key":"6192_CR28","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jamainternmed.2018.6989","volume":"179","author":"GP Guy Jr","year":"2019","unstructured":"Guy GP, Jr, Zhang K, Schieber LZ, Young R, Dowell D. County-Level Opioid Prescribing in the United States, 2015 and 2017County-Level Opioid Prescribing in the United States, 2015 and 2017Letters. JAMA Intern Med 2019;179:574\u2013576.","journal-title":"JAMA Intern Med"},{"key":"6192_CR29","doi-asserted-by":"crossref","unstructured":"Unick GJ, Ciccarone D. US regional and demographic differences in prescription opioid and heroin-related overdose hospitalizations. The International Journal on Drug Policy 2017;46:112\u2013119.","DOI":"10.1016\/j.drugpo.2017.06.003"},{"key":"6192_CR30","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/j.amepre.2017.09.003","volume":"54","author":"GP Guy","year":"2018","unstructured":"Guy GP, Pasalic E, Zhang K. Emergency Department Visits Involving Opioid Overdoses, U.S., 2010\u20132014. Am J Prev Med 2018;54:e37\u2013e39.","journal-title":"Am J Prev Med"},{"key":"6192_CR31","doi-asserted-by":"crossref","unstructured":"Green CA, Perrin NA, Hazlehurst B, et al. Identifying and classifying opioid-related overdoses: A validation study. Pharmacoepidemiol Drug Saf 2019.","DOI":"10.1002\/pds.4772"},{"key":"6192_CR32","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1177\/0033354918774330","volume":"133","author":"JM Buchanich","year":"2018","unstructured":"Buchanich JM, Balmert LC, Williams KE, Burke DS. The Effect of Incomplete Death Certificates on Estimates of Unintentional Opioid-Related Overdose Deaths in the United States, 1999-2015. Public Health Rep 2018;133:423-431.","journal-title":"Public Health Rep"},{"key":"6192_CR33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.23907\/2013.029","volume":"3","author":"M Warner","year":"2013","unstructured":"Warner M, Paulozzi LJ, Nolte KB, Davis GG, Nelson LS. State Variation in Certifying Manner of Death and Drugs Involved in Drug Intoxication Deaths. Academic Forensic Pathology 2013;3:231\u2013237.","journal-title":"Academic Forensic Pathology"},{"key":"6192_CR34","doi-asserted-by":"crossref","unstructured":"Carlson RG, Nahhas RW, Martins SS, Daniulaityte R. Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study. Drug Alcohol Depend. 2016;160:127\u2013134.","DOI":"10.1016\/j.drugalcdep.2015.12.026"},{"key":"6192_CR35","unstructured":"Muhuri PK, Gfroerer JC, Davies MC.Substance Abuse and Mental Health Services Administration. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. CBHSQ Data Review. Published August 2013. Accessed September 10, 2020."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-020-06192-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-020-06192-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-020-06192-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T02:37:50Z","timestamp":1631673470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-020-06192-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["6192"],"URL":"https:\/\/doi.org\/10.1007\/s11606-020-06192-4","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,15]]},"assertion":[{"value":"5 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Oregon Health & Science University Institutional Review Board (IRB) approval before obtaining the data. The data\u00a0were pre-existing de-identified health claims data, so we did not need to obtain informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Hartung reports grants from the Centers for Disease Control and Prevention, during the conduct of the study and grants from National Multiple Sclerosis Society, outside the submitted work. Ms. Johnston reports grants from the Centers for Disease Control and Prevention, during the conduct of the study. Ms. Hallvik reports grants from the Centers for Disease Control and Prevention, during the conduct of the study. Ms. Leichtling reports grants from the Centers for Disease Control and Prevention, during the conduct of the study. Mr. Geddes has nothing to disclose. Dr. Hildebran reports grants from the Centers for Disease Control and Prevention, during the conduct of the study. Dr. Keast reports grants from the Centers for Disease Control and Prevention, during the conduct of the study, grants from Otsuka Pharmaceuticals, and grants from Amgen, outside the submitted work. Dr. Chan has nothing to disclose. Dr. Korthuis reports grants from the Centers for Disease Control and Prevention, during the conduct of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}